BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Taimei Technology and C&R Research join hands to build AI-powered clinical trial innovation

May 11, 2026 | News

C&R Research will deploy Taimei Technology's leading digital infrastructure and AI Agents



US-based Taimei Technology, a leading artificial intelligence (AI)-powered drug clinical development platform company, and C&R Research, a top-tier CRO in South Korea, have signed an enterprise-level strategic partnership agreement for launching the development of an AI-based clinical trial operations system.

Under this partnership, C&R Research will deploy Taimei Technology's leading digital infrastructure and AI Agents across multiple clinical trials to automate and enhance trial design and operational workflows.

A particular focus will be on data management, where the EDC + iDM Agent combination will be actively adopted. Innovations such as intelligent data capture and governance, AI-driven eCRF generation, and automated test case creation are expected to boost productivity and quality in clinical research.

Leveraging its full-stack AI capabilities, 13 years of industry expertise, and global operational experience, Taimei Technology has deeply focused on the clinical research vertical, and has been among the first to build a comprehensive AI Agent matrix, enabling scenario-based AI applications across the entire clinical research workflow. Key offerings include eCollect (EDC), eBalance (RTSM), eCOA, eCooperate (CTMS), and eArchives (eTMF), iDM Agent, iCTA Agent, iPV Agent; as well as the iMAP intelligent medical analytics platform etc. These products can be flexibly configured to address critical pain points across clinical research—from efficiency to scientific insights—significantly improving trial efficiency and success rates.

The two companies plan to integrate AI-driven operational models with Korea's CRO-centric clinical trial execution system, thereby building a more efficient and intelligent clinical research framework.

Korea has established a mature ecosystem in innovative drug development and clinical execution, with clinical trial activity and participation in global pipelines ranking among the top worldwide. Industry observers believe this partnership goes beyond technology adoption and will serve as a key catalyst for accelerating the AI-driven digital transformation of South Korea's clinical trial landscape.